CyFlow CD34 FITC
| 品番 | CB940397 | ||
|---|---|---|---|
| 抗体名 | Anti-Hu CD34 FITC,QBEnd-10 | ||
| 包装単位 | 100 tests | ||
| 濃度 | - | ||
| 容量 | 2 ml | ||
| 関連製品 (アイソタイプコントロール) |
Mouse IgG1 FITC (CD051682) |
||
| 反応性|交差吸着 | Human | Non-Human Primates | レーザー | Blue |
| 抗原 | CD34 | 最大蛍光波長 | 518 nm |
| クローン | QBEnd-10 | 最大励起波長 | 490 to 495 nm |
| ホスト | Mouse | 標識/Format | FITC |
| アイソタイプ | IgG1 | 研究分野 | Immunophenotyping |
| クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD34 FITC,QBEnd-10
特異性
The mouse monoclonal antibody QBEnd-10 recognizes Class II epitope on CD34 antigen, a 110-115 kDa monomeric transmembrane phosphoglycoprotein expressed on hematopoietic progenitors cells and on the most pluripotential stem cells; it is gradually lost on progenitor cells. This antibody has been also used as an endothelial marker.
抗原情報
CD34 (Mucosialin) is a highly glycosylated monomeric 111-115 kDa surface protein, which is present on many stem cell populations. It is a well established stem cell marker, though its expression on human hematopoietic stem cells is reversible. CD34 probably serves as a surface receptor that undergoes receptor-mediated endocytosis and regulates adhesion, differentiation and proliferation of hematopoietic stem cells and other progenitors. CD34 expression is likely to represent a specific state of hematopoietic development that may have altered adhering properties with expanding and differentiating capabilities in both in vitro and in vivo conditions.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 20 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Dao MA, Arevalo J, Nolta JA: Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for secondary reconstitution. Blood. 2003·Jan·1; 101(1):112‑8. <·PMID:·12589631·>
• Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Gulati S, Luthra PM: Three‑dimensional structure prediction of the interaction of CD34 with the SH3 domain of Crk‑L. Stem·Cells·Dev. 2005·Oct; 14(5):470‑7. <·PMID:·16305332·>
• Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Luthra PM: Hematopoietic stem cell antigen CD34: role in adhesion or homing. Stem·Cells·Dev. 2006·Jun; 15(3):305‑13. <·PMID:·16846369·>
• Grimsley PG, Amos TA, Gordon MY, Greaves MF: Rapid positive selection of CD34+ cells using magnetic microspheres coated with monoclonal antibody QBEND/10 linked via a cleavable disulphide bond. Leukemia. 1993·Jun; 7(6):898‑908. <·PMID:·7684800·>
• Krauter J, Hartl M, Hambach L, Kohlenberg A, Gunsilius E, Ganser A, Heil G: Receptor‑mediated endocytosis of CD34 on hematopoietic cells after stimulation with the monoclonal antibody anti‑HPCA‑1. J·Hematother·Stem·Cell·Res. 2001·Dec; 10(6):863‑71. <·PMID:·11798512·>
• Kuzu I, Bicknell R, Harris AL, Jones M, Gatter KC, Mason DY: Heterogeneity of vascular endothelial cells with relevance to diagnosis of vascular tumours. J·Clin·Pathol. 1992·Feb; 45(2):143‑8. <·PMID:·1371777·>
• Poblet E, Jimenez-Acosta F, Rocamora A: QBEND/10 (anti‑CD34 antibody) in external root sheath cells and follicular tumors. J·Cutan·Pathol. 1994·Jun; 21(3):224‑8. <·PMID:·7525669·>
• Ramani P, Bradley NJ, Fletcher CD: QBEND/10, a new monoclonal antibody to endothelium: assessment of its diagnostic utility in paraffin sections. Histopathology. 1990·Sep; 17(3):237‑42. <·PMID:·2242851·>
• Schlingemann RO, Rietveld FJ, de Waal RM, Bradley NJ, Skene AI, Davies AJ, Greaves MF, Denekamp J, Ruiter DJ: Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab·Invest. 1990·Jun; 62(6):690‑6. <·PMID:·1694254·>
• Sutherland DR, Marsh JC, Davidson J, Baker MA, Keating A, Mellors A: Differential sensitivity of CD34 epitopes to cleavage by Pasteurella haemolytica glycoprotease: implications for purification of CD34‑positive progenitor cells. Exp·Hematol. 1992·Jun; 20(5):590‑9. <·PMID:·1375160·>
• Traoré Y, Hirn J: Certain anti‑CD34 monoclonal antibodies induce homotypic adhesion of leukemic cell lines in a CD18‑dependent and a CD18‑independent way. Eur·J·Immunol. 1994·Oct; 24(10):2304‑11. <·PMID:·7523134·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN